BlueWillow Biologics

About:

BlueWillow is a biopharmaceutical company that focuses on developing and commercializing topical antiseptic and anti-infective products.

Website: http://www.bluewillow.com

Twitter/X: nanobio

Top Investors: National Institute of Allergy and Infectious Diseases, Bill & Melinda Gates Foundation, Small Business Innovation Research, Venture Investors, Wolverine Venture Fund

Description:

BlueWillow Biologics operates as a clinical-stage, privately-held biopharmaceutical company. It focuses on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. Its platform employs novel oil-in-water nano-droplets for products administered to the skin and nose. The company was founded as a spin-off from the University of Michigan and is headquartered in Ann Arbor, Michigan.

Total Funding Amount:

$86.3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Ann Arbor, Michigan, United States

Founded Date:

2000-01-01

Contact Email:

john.coffey(AT)nanobio.com

Founders:

James R Baker

Number of Employees:

11-50

Last Funding Date:

2018-09-26

IPO Status:

Private

Industries:

© 2025 bioDAO.ai